At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Laboratory Biomarker Analysis, and 3 other interventions for Giant Cell Glioblastoma and 5 related conditions. Completed, enrolled 137 participants across 244 sites in 2 countries.
Detailed Summary
This partially randomized phase II trial with a safety run-in component studies the side effects and how well bevacizumab given with or without trebananib works in treating patients with brain tumors that have come back (recurrent). Immunotherapy with monoclonal antibodies, such as bevacizumab, may induce changes in the body's immune system and interfere with the ability of tumor cells to grow and spread. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving bevacizumab together with trebananib is more effective than bevacizumab alone in treating brain tumors.
Study Details
Timeline
Interventions
Given IV
Correlative studies
Correlative studies
Given IV
Given IV